Tag: specific antiviral drugs for covid 19 market size

Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.

Specific Antiviral Drugs For COVID 19 Market Forecast: What Value Will The Market Reach By 2030?

The market size for specific antiviral drugs for covid 19 has witnessed rapid expansion in recent years. It is forecast to increase from $15.23 billion in 2025 to $17.83 billion in 2026, achieving a compound annual growth rate (CAGR) of 17.1%. Several factors contributed to its growth in the past, including the swift spread of covid-19, the issuance of emergency use authorizations, the reliance on established antiviral drug classes, limitations in global production capacity, and elevated rates of hospitalization.

The market for specific antiviral drugs for covid 19 is poised for considerable expansion in the upcoming years. It is anticipated to achieve a valuation of $33.17 billion by 2030, growing at a compound annual growth rate (CAGR) of 16.8%. This growth throughout the forecast period can be attributed to several factors, including the advancement of next-generation antiviral drugs, an increase in public-private partnerships, the rising adoption of preventive treatments, the expansion of combination therapies, and the integration of personalized medicine approaches. Key trends expected during this period involve a surge in investment for covid-19 antiviral drug development, the increasing use of oral antiviral tablets, the growth of monoclonal antibody therapies, the broadening of hospital and retail distribution channels, and a focused effort on targeted treatment for hospitalized and high-risk patients.

Get A Free Sample Report With In-Depth Market Insights:

https://thebusinessresearchcompany.com/sample_request?id=37104444&type=smp&name=Specific%20Antiviral%20Drugs%20For%20COVID%2019%20Market%20Report%202026&utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Specific Antiviral Drugs For COVID 19 Market Growth Momentum: What Factors Are Shaping Demand?

The escalating count of COVID-19 infections is anticipated to stimulate the future expansion of the specific antiviral drugs for the COVID-19 market. COVID-19 cases pertain to individuals who have tested positive for the SARS-CoV-2 virus, which is responsible for COVID-19. The increase in COVID-19 cases is attributable to the emergence of new variants that exhibit easier transmission and a partial ability to evade immunity from prior vaccinations or infections. Specific antiviral drugs for COVID-19 are beneficial in mitigating the illness’s severity and duration, thus enhancing patient outcomes and reducing the overall impact of COVID-19 cases. For example, in May 2025, the World Health Organization, a global public health agency based in Switzerland, reported that the Eastern Mediterranean region’s test positivity rate surged from 4% to 17% in early 2025, surpassing the figures for the equivalent period in 2024. This rising number of COVID-19 cases therefore propels the growth of the specific antiviral drugs for the COVID-19 market.

Specific Antiviral Drugs For COVID 19 Market Breakdown By Product Type And Application

The specific antiviral drugs for covid 19 market covered in this report is segmented –

1) By Type: Tablet, Injection

2) By Indication: Hospitalized Patients, Non-Hospitalized Patients, Preventive Treatment

3) By Drug Class: Nucleoside Analogues, Protease Inhibitors, Ribonucleic Acid Polymerase Inhibitors, Entry Inhibitors, Monoclonal Antibodies

4) By Route Of Administration: Oral, Intravenous, Subcutaneous, Inhalation

5) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Other Distribution Channels

Subsegments:

1) By Tablet: Oral Antiviral Tablets, Combination Antiviral Tablets, Extended-Release Tablets

2) By Injection: Intravenous (IV) Antiviral Injections, Intramuscular (IM) Antiviral Injections, Subcutaneous Antiviral Injections

Specific Antiviral Drugs For COVID 19 Market Trends Redefining Industry Growth

Key players within the specific antiviral drugs for the COVID-19 market are concentrating their efforts on creating groundbreaking treatments, like oral antiviral therapies, aimed at improving both the availability and efficacy of care. Oral antiviral therapies are medications administered orally to prevent the replication of viruses such as COVID-19, providing a practical and potent treatment solution. As an illustration, in March 2024, Shionogi And Co., a pharmaceutical company based in Japan, released Xocova and received full standard endorsement from Japan’s Ministry of Health, Labour and Welfare (MHLW) for its antiviral drug ensitrelvir. Moreover, it also delivers post-exposure prophylaxis by considerably decreasing the chance of symptomatic COVID-19 developing in individuals who have been exposed, and it shortens the duration of symptoms while demonstrating a positive safety profile.

Specific Antiviral Drugs For COVID 19 Market Company Landscape And Competitive Strategy

Major companies operating in the specific antiviral drugs for covid 19 market are Pfizer Inc., Merck & Co. Inc., Gilead Sciences Inc., Shionogi & Co. Ltd., Cipla Limited, Hetero Drugs Limited, Roche Holding AG, Johnson & Johnson, Novartis AG, GSK plc, Eli Lilly and Company, Regeneron Pharmaceuticals Inc., Sun Pharmaceutical Industries Ltd., Beximco Pharmaceuticals Limited, Atea Pharmaceuticals Inc., Enanta Pharmaceuticals Inc., RedHill Biopharma Ltd., Synairgen plc, Dr. Reddy’s Laboratories Ltd., Aurobindo Pharma Ltd., Lupin Limited, Natco Pharma Ltd., Zydus Lifesciences Ltd., Viatris Inc., Teva Pharmaceutical Industries Ltd., Hikma Pharmaceuticals PLC, Alkem Laboratories Ltd., Torrent Pharmaceuticals Ltd., Apotex Inc., Mylan N.V.

View The Full Specific Antiviral Drugs For COVID 19 Market Report:

https://thebusinessresearchcompany.com/report/specific-antiviral-drugs-for-covid-19-global-market-report?utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Specific Antiviral Drugs For COVID 19 Market Global Footprint: Which Region Leads The Industry?

North America was the largest region in the specific antiviral drugs for COVID 19 market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the specific antiviral drugs for covid 19 market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Reach Out To Our Team:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.

Specific Antiviral Drugs For COVID 19 Market Size And Revenue Forecast Through 2030

The market for specific antiviral drugs targeting COVID-19 has experienced notable expansion in recent years, climbing from $15.23 billion in 2025 to an estimated $17.83 billion in 2026, reflecting a compound annual growth rate (CAGR) of 17.1%. This historical growth was driven by several key factors, including the swift transmission of the COVID-19 virus, the granting of emergency use authorizations, a dependence on established antiviral drug categories, constrained manufacturing capabilities on a global scale, and elevated rates of hospitalization.

The market for specific antiviral drugs targeting COVID-19 is anticipated to experience significant expansion in the coming years. It is projected to reach $33.17 billion by 2030, achieving a compound annual growth rate (CAGR) of 16.8%. Growth during this forecast period is driven by factors such as the creation of advanced antiviral agents, enhanced collaborations between public and private sectors, greater uptake of preventive treatments, broader use of combination therapies, and the incorporation of personalized medicine strategies. Key trends shaping this period include heightened investment in the creation of COVID-19 antiviral drugs, a surge in the use of oral antiviral tablets, progress in monoclonal antibody treatments, wider availability through hospital and retail pharmacy networks, and a greater emphasis on specific treatments for hospitalized and high-risk individuals.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24713&type=smp&utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Specific Antiviral Drugs For COVID 19 Market Demand Drivers Creating New Revenue Opportunities

The anticipated growth of the specific antiviral drugs market for COVID-19 is being driven by the increasing number of confirmed cases. These cases represent individuals who have tested positive for SARS-CoV-2, the virus responsible for COVID-19. This surge in infections is largely attributed to newly emerging variants that are more transmissible and possess the ability to partially bypass immunity gained from prior vaccinations or previous infections. Antiviral medications specifically designed for COVID-19 play a crucial role in lessening the severity and shortening the duration of the illness, which enhances patient recovery and reduces the overall strain caused by the pandemic. To illustrate, data released by the World Health Organization—a global public health body based in Switzerland—in May 2025 showed that the test positivity rate in the Eastern Mediterranean region surged from 4% to 17% during early 2025, exceeding figures recorded in the corresponding period of 2024. Consequently, the escalating number of COVID-19 cases is fueling expansion in the specific antiviral drugs market for this disease.

Specific Antiviral Drugs For COVID 19 Market Segment Landscape And Growth Potential

The specific antiviral drugs for covid 19 market covered in this report is segmented –

1) By Type: Tablet, Injection

2) By Indication: Hospitalized Patients, Non-Hospitalized Patients, Preventive Treatment

3) By Drug Class: Nucleoside Analogues, Protease Inhibitors, Ribonucleic Acid Polymerase Inhibitors, Entry Inhibitors, Monoclonal Antibodies

4) By Route Of Administration: Oral, Intravenous, Subcutaneous, Inhalation

5) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Other Distribution Channels

Subsegments:

1) By Tablet: Oral Antiviral Tablets, Combination Antiviral Tablets, Extended-Release Tablets

2) By Injection: Intravenous (IV) Antiviral Injections, Intramuscular (IM) Antiviral Injections, Subcutaneous Antiviral Injections

Specific Antiviral Drugs For COVID 19 Market Trends Driving Strategic Industry Expansion

Key players within the specific antiviral drugs market for COVID-19 are concentrating on creating novel treatments, particularly oral antiviral therapies, aimed at improving both accessibility and effectiveness of care. These oral antiviral agents, ingested as pills, function by stopping the replication of viruses such as COVID-19, providing a convenient and efficient therapeutic approach. In March 2024, for example, Shionogi & Co., a pharmaceutical firm based in Japan, introduced Xocova and secured full standard approval from Japan’s Ministry of Health, Labour and Welfare (MHLW) for the antiviral drug ensitrelvir. Moreover, this drug serves as a post-exposure prophylaxis, notably lowering the likelihood of developing symptomatic COVID-19 among exposed individuals while also decreasing symptom duration and maintaining a favorable safety profile.

Specific Antiviral Drugs For COVID 19 Market Competitive Landscape: Who Are The Leading Companies?

Major companies operating in the specific antiviral drugs for covid 19 market are Pfizer Inc., Merck & Co. Inc., Gilead Sciences Inc., Shionogi & Co. Ltd., Cipla Limited, Hetero Drugs Limited, Roche Holding AG, Johnson & Johnson, Novartis AG, GSK plc, Eli Lilly and Company, Regeneron Pharmaceuticals Inc., Sun Pharmaceutical Industries Ltd., Beximco Pharmaceuticals Limited, Atea Pharmaceuticals Inc., Enanta Pharmaceuticals Inc., RedHill Biopharma Ltd., Synairgen plc, Dr. Reddy’s Laboratories Ltd., Aurobindo Pharma Ltd., Lupin Limited, Natco Pharma Ltd., Zydus Lifesciences Ltd., Viatris Inc., Teva Pharmaceutical Industries Ltd., Hikma Pharmaceuticals PLC, Alkem Laboratories Ltd., Torrent Pharmaceuticals Ltd., Apotex Inc., Mylan N.V.

Access The Complete Specific Antiviral Drugs For COVID 19 Market Report:

https://www.thebusinessresearchcompany.com/report/specific-antiviral-drugs-for-covid-19-global-market-report?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Specific Antiviral Drugs For COVID 19 Market Regional Outlook: Where Are The Largest Opportunities Located?

North America was the largest region in the specific antiviral drugs for COVID 19 market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the specific antiviral drugs for covid 19 market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.

Specific Antiviral Drugs For COVID 19 Market Size And Revenue Forecast Through 2030

The market for specific antiviral drugs targeting COVID-19 has experienced notable expansion in recent years, climbing from $15.23 billion in 2025 to an estimated $17.83 billion in 2026, reflecting a compound annual growth rate (CAGR) of 17.1%. This historical growth was driven by several key factors, including the swift transmission of the COVID-19 virus, the granting of emergency use authorizations, a dependence on established antiviral drug categories, constrained manufacturing capabilities on a global scale, and elevated rates of hospitalization.

The market for specific antiviral drugs targeting COVID-19 is anticipated to experience significant expansion in the coming years. It is projected to reach $33.17 billion by 2030, achieving a compound annual growth rate (CAGR) of 16.8%. Growth during this forecast period is driven by factors such as the creation of advanced antiviral agents, enhanced collaborations between public and private sectors, greater uptake of preventive treatments, broader use of combination therapies, and the incorporation of personalized medicine strategies. Key trends shaping this period include heightened investment in the creation of COVID-19 antiviral drugs, a surge in the use of oral antiviral tablets, progress in monoclonal antibody treatments, wider availability through hospital and retail pharmacy networks, and a greater emphasis on specific treatments for hospitalized and high-risk individuals.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24713&type=smp&utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Specific Antiviral Drugs For COVID 19 Market Demand Drivers Creating New Revenue Opportunities

The anticipated growth of the specific antiviral drugs market for COVID-19 is being driven by the increasing number of confirmed cases. These cases represent individuals who have tested positive for SARS-CoV-2, the virus responsible for COVID-19. This surge in infections is largely attributed to newly emerging variants that are more transmissible and possess the ability to partially bypass immunity gained from prior vaccinations or previous infections. Antiviral medications specifically designed for COVID-19 play a crucial role in lessening the severity and shortening the duration of the illness, which enhances patient recovery and reduces the overall strain caused by the pandemic. To illustrate, data released by the World Health Organization—a global public health body based in Switzerland—in May 2025 showed that the test positivity rate in the Eastern Mediterranean region surged from 4% to 17% during early 2025, exceeding figures recorded in the corresponding period of 2024. Consequently, the escalating number of COVID-19 cases is fueling expansion in the specific antiviral drugs market for this disease.

Specific Antiviral Drugs For COVID 19 Market Segment Landscape And Growth Potential

The specific antiviral drugs for covid 19 market covered in this report is segmented –

1) By Type: Tablet, Injection

2) By Indication: Hospitalized Patients, Non-Hospitalized Patients, Preventive Treatment

3) By Drug Class: Nucleoside Analogues, Protease Inhibitors, Ribonucleic Acid Polymerase Inhibitors, Entry Inhibitors, Monoclonal Antibodies

4) By Route Of Administration: Oral, Intravenous, Subcutaneous, Inhalation

5) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Other Distribution Channels

Subsegments:

1) By Tablet: Oral Antiviral Tablets, Combination Antiviral Tablets, Extended-Release Tablets

2) By Injection: Intravenous (IV) Antiviral Injections, Intramuscular (IM) Antiviral Injections, Subcutaneous Antiviral Injections

Specific Antiviral Drugs For COVID 19 Market Trends Driving Strategic Industry Expansion

Key players within the specific antiviral drugs market for COVID-19 are concentrating on creating novel treatments, particularly oral antiviral therapies, aimed at improving both accessibility and effectiveness of care. These oral antiviral agents, ingested as pills, function by stopping the replication of viruses such as COVID-19, providing a convenient and efficient therapeutic approach. In March 2024, for example, Shionogi & Co., a pharmaceutical firm based in Japan, introduced Xocova and secured full standard approval from Japan’s Ministry of Health, Labour and Welfare (MHLW) for the antiviral drug ensitrelvir. Moreover, this drug serves as a post-exposure prophylaxis, notably lowering the likelihood of developing symptomatic COVID-19 among exposed individuals while also decreasing symptom duration and maintaining a favorable safety profile.

Specific Antiviral Drugs For COVID 19 Market Competitive Landscape: Who Are The Leading Companies?

Major companies operating in the specific antiviral drugs for covid 19 market are Pfizer Inc., Merck & Co. Inc., Gilead Sciences Inc., Shionogi & Co. Ltd., Cipla Limited, Hetero Drugs Limited, Roche Holding AG, Johnson & Johnson, Novartis AG, GSK plc, Eli Lilly and Company, Regeneron Pharmaceuticals Inc., Sun Pharmaceutical Industries Ltd., Beximco Pharmaceuticals Limited, Atea Pharmaceuticals Inc., Enanta Pharmaceuticals Inc., RedHill Biopharma Ltd., Synairgen plc, Dr. Reddy’s Laboratories Ltd., Aurobindo Pharma Ltd., Lupin Limited, Natco Pharma Ltd., Zydus Lifesciences Ltd., Viatris Inc., Teva Pharmaceutical Industries Ltd., Hikma Pharmaceuticals PLC, Alkem Laboratories Ltd., Torrent Pharmaceuticals Ltd., Apotex Inc., Mylan N.V.

Access The Complete Specific Antiviral Drugs For COVID 19 Market Report:

https://www.thebusinessresearchcompany.com/report/specific-antiviral-drugs-for-covid-19-global-market-report?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Specific Antiviral Drugs For COVID 19 Market Regional Outlook: Where Are The Largest Opportunities Located?

North America was the largest region in the specific antiviral drugs for COVID 19 market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the specific antiviral drugs for covid 19 market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

What Is The Forecasted Rise In Market Size Of The Specific Antiviral Drugs For COVID 19 Market During The Forecast Period?

The market for specific antiviral drugs designed for COVID-19 has experienced swift expansion over recent years. It is projected to expand from $15.23 billion in 2025 to $17.83 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 17.1%. The growth witnessed during the preceding period stemmed from factors such as the swift global dissemination of COVID-19, the issuance of emergency use authorizations, continued dependence on established antiviral drug categories, constraints in worldwide production capacity, and elevated rates of hospitalization.

The market for specific antiviral drugs used to treat covid 19 is anticipated to experience substantial growth in the upcoming years. It is projected to reach $33.17 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 16.8%. Factors contributing to this growth during the forecast period include the advancement of next-generation antiviral medications, a rise in public-private collaborations, increased acceptance of preventive treatments, the broadening use of combination therapies, and the incorporation of personalized medicine strategies. Key trends anticipated during this period encompass escalating investment in covid-19 antiviral drug research and development, wider uptake of oral antiviral tablets, an increase in monoclonal antibody treatments, an expansion of both hospital and retail distribution networks, and a concentrated effort on targeted treatments for patients who are hospitalized or at high risk.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24713&type=smp

What Important Drivers Are Powering The Specific Antiviral Drugs For COVID 19 Market Growth?

An increase in COVID-19 infections is anticipated to boost the specific antiviral drugs for the COVID-19 market in the future. COVID-19 cases are defined as persons confirmed positive for the SARS-CoV-2 virus, the pathogen responsible for the disease. This surge in COVID-19 cases stems from the emergence of novel variants, characterized by increased transmissibility and a partial ability to bypass immunity acquired through vaccination or prior illness. These specific antiviral drugs for COVID-19 mitigate the illness’s intensity and length, leading to better patient outcomes and lessening the overall impact of COVID-19 infections. For example, the World Health Organization, a global public health agency based in Switzerland, reported in May 2025 that the Eastern Mediterranean region experienced a rise in its test positivity rate from 4% to 17% in early 2025, exceeding the rate from the corresponding period in 2024. Consequently, the escalating number of COVID-19 infections is a key factor driving the expansion of the specific antiviral drugs for the COVID-19 market.

How Are Different Segment Groups Identified Within The Specific Antiviral Drugs For COVID 19 Market?

The specific antiviral drugs for covid 19 market covered in this report is segmented –

1) By Type: Tablet, Injection

2) By Indication: Hospitalized Patients, Non-Hospitalized Patients, Preventive Treatment

3) By Drug Class: Nucleoside Analogues, Protease Inhibitors, Ribonucleic Acid Polymerase Inhibitors, Entry Inhibitors, Monoclonal Antibodies

4) By Route Of Administration: Oral, Intravenous, Subcutaneous, Inhalation

5) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Other Distribution Channels

Subsegments:

1) By Tablet: Oral Antiviral Tablets, Combination Antiviral Tablets, Extended-Release Tablets

2) By Injection: Intravenous (IV) Antiviral Injections, Intramuscular (IM) Antiviral Injections, Subcutaneous Antiviral Injections

Which Trends Are Contributing To Changes In The Specific Antiviral Drugs For COVID 19 Market?

Key players in the specialized antiviral drugs for the COVID-19 market are prioritizing the creation of groundbreaking treatments, particularly oral antiviral therapies, to boost both the availability and efficacy of care. Oral antiviral therapies refer to medicines ingested orally to halt the reproduction of viruses like COVID-19, thus presenting a convenient and potent treatment choice. For instance, in March 2024, Shionogi And Co., a pharmaceutical company based in Japan, introduced Xocova and received full standard approval for the antiviral drug ensitrelvir from Japan’s Ministry of Health, Labour and Welfare (MHLW). Moreover, it also delivers post-exposure prophylaxis by considerably lessening the chances of exposed individuals developing symptomatic COVID-19 and truncating symptom duration, along with a commendable safety profile.

Which Firms Are Competing In The Specific Antiviral Drugs For COVID 19 Market?

Major companies operating in the specific antiviral drugs for covid 19 market are Pfizer Inc., Merck & Co. Inc., Gilead Sciences Inc., Shionogi & Co. Ltd., Cipla Limited, Hetero Drugs Limited, Roche Holding AG, Johnson & Johnson, Novartis AG, GSK plc, Eli Lilly and Company, Regeneron Pharmaceuticals Inc., Sun Pharmaceutical Industries Ltd., Beximco Pharmaceuticals Limited, Atea Pharmaceuticals Inc., Enanta Pharmaceuticals Inc., RedHill Biopharma Ltd., Synairgen plc, Dr. Reddy’s Laboratories Ltd., Aurobindo Pharma Ltd., Lupin Limited, Natco Pharma Ltd., Zydus Lifesciences Ltd., Viatris Inc., Teva Pharmaceutical Industries Ltd., Hikma Pharmaceuticals PLC, Alkem Laboratories Ltd., Torrent Pharmaceuticals Ltd., Apotex Inc., Mylan N.V.

Access The Complete Specific Antiviral Drugs For COVID 19 Market Report:

https://www.thebusinessresearchcompany.com/report/specific-antiviral-drugs-for-covid-19-global-market-report

Which Region Leads The Specific Antiviral Drugs For COVID 19 Market By Size?

North America was the largest region in the specific antiviral drugs for COVID 19 market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the specific antiviral drugs for covid 19 market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Specific Antiviral Drugs For COVID 19 Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/sample.aspx?id=24713&type=smp

Browse Through More Reports Similar to the Global Specific Antiviral Drugs For COVID 19 Market 2026, By The Business Research Company

Antivirals Market Report 2026

https://www.thebusinessresearchcompany.com/report/antivirals-global-market-report

The Antiviral And Antimicrobial Coatings Market Report 2026

https://www.thebusinessresearchcompany.com/report/the-antiviral-and-antimicrobial-coatings-global-market-report

Antiviral Combination Therapy Market Report 2026

https://www.thebusinessresearchcompany.com/report/antiviral-combination-therapy-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Value Is Anticipated For The Specific Antiviral Drugs For COVID 19 Market Over The Period 2026–2030?

The market size for specific antiviral drugs targeting covid 19 has expanded quickly in recent years. It is projected to increase from $15.23 billion in 2025 to $17.83 billion by 2026, exhibiting a compound annual growth rate (CAGR) of 17.1%. Historically, this expansion can be linked to the rapid dissemination of covid-19, emergency use authorizations, the reliance on traditional antiviral drug classifications, limited global production capabilities, and high hospitalization rates.

The specific antiviral drugs for covid 19 market size is projected to experience swift expansion over the coming years. This market is anticipated to reach a valuation of $33.17 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 16.8%. The projected growth during this period can be ascribed to several factors, including the advancement of next-generation antiviral medications, an increase in collaborations between public and private entities, a rise in the uptake of preventive treatments, the broadening use of combination therapies, and the incorporation of personalized medicine strategies. Key trends expected during the forecast period encompass greater investment in the development of COVID-19 antiviral drugs, an increasing preference for oral antiviral tablets, an expansion of monoclonal antibody-based treatments, the widening of hospital and retail distribution networks, and a concentrated effort on providing targeted therapies for patients who are hospitalized or at high risk.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24713&type=smp

What Drivers Are Expected To Influence The Specific Antiviral Drugs For COVID 19 Market During The Forecast Period?

An increasing number of COVID-19 cases is projected to stimulate the expansion of the specific antiviral drugs for the COVID-19 market going forward. COVID-19 cases refer to individuals confirmed positive for the SARS-CoV-2 virus, which is the cause of COVID-19. This surge in COVID-19 cases is attributed to the emergence of new variants that demonstrate easier transmission and can partially evade immunity from vaccines or prior infections. Specific antiviral drugs for COVID-19 are beneficial in reducing the severity and duration of the illness, leading to improved patient outcomes and a lower overall burden from COVID-19 cases. For instance, in May 2025, the World Health Organization, a Switzerland-based global public health agency, indicated that the Eastern Mediterranean region’s test positivity rate surged from 4% to 17% in early 2025, surpassing the rate from the identical period in 2024. Therefore, the escalating number of COVID-19 cases fuels the growth of the specific antiviral drugs for the COVID-19 market.

How Is The Specific Antiviral Drugs For COVID 19 Market Divided Into Its Major Segments?

The specific antiviral drugs for covid 19 market covered in this report is segmented –

1) By Type: Tablet, Injection

2) By Indication: Hospitalized Patients, Non-Hospitalized Patients, Preventive Treatment

3) By Drug Class: Nucleoside Analogues, Protease Inhibitors, Ribonucleic Acid Polymerase Inhibitors, Entry Inhibitors, Monoclonal Antibodies

4) By Route Of Administration: Oral, Intravenous, Subcutaneous, Inhalation

5) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Other Distribution Channels

Subsegments:

1) By Tablet: Oral Antiviral Tablets, Combination Antiviral Tablets, Extended-Release Tablets

2) By Injection: Intravenous (IV) Antiviral Injections, Intramuscular (IM) Antiviral Injections, Subcutaneous Antiviral Injections

How Are Trends Transforming The Specific Antiviral Drugs For COVID 19 Market Landscape?

Leading companies in the specific antiviral drugs for the COVID-19 market are concentrating on developing innovative treatments, such as oral antiviral therapies, to improve both accessibility and effectiveness of care. These oral antiviral therapies are medicines taken by mouth to prevent the replication of viruses like COVID-19, presenting a convenient and efficient treatment choice. For example, in March 2024, Shionogi And Co., a pharmaceutical company located in Japan, launched Xocova and received full standard approval from Japan’s Ministry of Health, Labour and Welfare (MHLW) for the antiviral drug ensitrelvir. Additionally, this drug also provides post-exposure prophylaxis by considerably decreasing the risk of symptomatic COVID-19 among exposed individuals and reduces the length of symptoms with a positive safety record.

Who Are The Prominent Organizations Shaping The Specific Antiviral Drugs For COVID 19 Market?

Major companies operating in the specific antiviral drugs for covid 19 market are Pfizer Inc., Merck & Co. Inc., Gilead Sciences Inc., Shionogi & Co. Ltd., Cipla Limited, Hetero Drugs Limited, Roche Holding AG, Johnson & Johnson, Novartis AG, GSK plc, Eli Lilly and Company, Regeneron Pharmaceuticals Inc., Sun Pharmaceutical Industries Ltd., Beximco Pharmaceuticals Limited, Atea Pharmaceuticals Inc., Enanta Pharmaceuticals Inc., RedHill Biopharma Ltd., Synairgen plc, Dr. Reddy’s Laboratories Ltd., Aurobindo Pharma Ltd., Lupin Limited, Natco Pharma Ltd., Zydus Lifesciences Ltd., Viatris Inc., Teva Pharmaceutical Industries Ltd., Hikma Pharmaceuticals PLC, Alkem Laboratories Ltd., Torrent Pharmaceuticals Ltd., Apotex Inc., Mylan N.V.

Read the full specific antiviral drugs for covid 19 market report here:

https://www.thebusinessresearchcompany.com/report/specific-antiviral-drugs-for-covid-19-global-market-report

Which Region Is Forecast To Lead The Specific Antiviral Drugs For COVID 19 Market In Terms Of Market Size?

North America was the largest region in the specific antiviral drugs for COVID 19 market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the specific antiviral drugs for covid 19 market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Specific Antiviral Drugs For COVID 19 Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=24713&type=smp

Browse Through More Reports Similar to the Global Specific Antiviral Drugs For COVID 19 Market 2026, By The Business Research Company

Antivirals Market Report 2026

https://www.thebusinessresearchcompany.com/report/antivirals-global-market-report

The Antiviral And Antimicrobial Coatings Market Report 2026

https://www.thebusinessresearchcompany.com/report/the-antiviral-and-antimicrobial-coatings-global-market-report

Antiviral Combination Therapy Market Report 2026

https://www.thebusinessresearchcompany.com/report/antiviral-combination-therapy-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the specific antiviral drugs for covid 19 market from 2026–2035 with trusted insights from The Business Research Company

How much is the Specific Antiviral Drugs For COVID 19 Market valued at in 2026, and what valuation is forecast for 2030?

The market size for specific antiviral drugs addressing COVID-19 has seen considerable expansion in recent years. This market is projected to expand from $15.23 billion in 2025 to $17.83 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 17.1%. Factors contributing to its historical growth include the swift dissemination of COVID-19, the issuance of emergency use authorizations, a reliance on established antiviral drug categories, constrained global manufacturing capabilities, and elevated hospitalization rates.

The market size for specific antiviral drugs for covid 19 is anticipated to undergo significant expansion in the coming years, with projections indicating a rise to $33.17 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 16.8%. This expansion during the forecast period is driven by the development of next-generation antiviral drugs, increased public-private partnerships, a rise in the adoption of preventive treatments, the broadening of combination therapies, and the incorporation of personalized medicine approaches. Prominent trends within this forecast period include increasing investment in covid-19 antiviral drug development, a growing uptake of oral antiviral tablets, the advancement of monoclonal antibody therapies, the expansion of hospital and retail distribution channels, and an emphasis on targeted treatment for hospitalized and high-risk patients.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24713&type=smp

What Drivers Are Influencing The Growth Of The Specific Antiviral Drugs For COVID 19 Market?

The anticipated rise in COVID-19 cases is set to stimulate the growth of the specific antiviral drugs for the COVID-19 market moving forward. COVID-19 cases signify individuals who have tested positive for the SARS-CoV-2 virus, which causes the disease. This increase in COVID-19 cases can be attributed to the appearance of new variants that spread more readily and can partly bypass immunity gained from vaccines or previous infections. Specific antiviral drugs for COVID-19 are crucial for reducing the illness’s severity and duration, leading to improved patient outcomes and a decrease in the overall impact of COVID-19 cases. For example, in May 2025, the World Health Organization, a global public health agency based in Switzerland, reported that the Eastern Mediterranean region’s test positivity rate escalated from 4% to 17% in early 2025, a figure higher than the corresponding period in 2024. Thus, the escalating count of COVID-19 cases is a significant driver for the expansion of the specific antiviral drugs for the COVID-19 market.

What Segments Are Included Within The Specific Antiviral Drugs For COVID 19 Market?

The specific antiviral drugs for covid 19 market covered in this report is segmented –

1) By Type: Tablet, Injection

2) By Indication: Hospitalized Patients, Non-Hospitalized Patients, Preventive Treatment

3) By Drug Class: Nucleoside Analogues, Protease Inhibitors, Ribonucleic Acid Polymerase Inhibitors, Entry Inhibitors, Monoclonal Antibodies

4) By Route Of Administration: Oral, Intravenous, Subcutaneous, Inhalation

5) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Other Distribution Channels

Subsegments:

1) By Tablet: Oral Antiviral Tablets, Combination Antiviral Tablets, Extended-Release Tablets

2) By Injection: Intravenous (IV) Antiviral Injections, Intramuscular (IM) Antiviral Injections, Subcutaneous Antiviral Injections

How Are Emerging Trends Affecting The Progression Of The Specific Antiviral Drugs For COVID 19 Market?

Leading companies operating within the specific antiviral drugs for the COVID-19 market are concentrating on developing innovative treatments, such as oral antiviral therapies, to improve the accessibility and effectiveness of care. Oral antiviral therapies are medications consumed by mouth to inhibit the replication of viruses like COVID-19, thereby offering a convenient and effective treatment alternative. For example, in March 2024, Shionogi And Co., a Japan-based pharmaceutical company, launched Xocova and received full standard approval from Japan’s Ministry of Health, Labour and Welfare (MHLW) for the antiviral drug ensitrelvir. Additionally, this drug also offers post-exposure prophylaxis by significantly reducing the risk of developing symptomatic COVID-19 in exposed individuals and shortens symptom duration with a favorable safety profile.

Who Are The Core Companies Influencing Trends In The Specific Antiviral Drugs For COVID 19 Market?

Major companies operating in the specific antiviral drugs for covid 19 market are Pfizer Inc., Merck & Co. Inc., Gilead Sciences Inc., Shionogi & Co. Ltd., Cipla Limited, Hetero Drugs Limited, Roche Holding AG, Johnson & Johnson, Novartis AG, GSK plc, Eli Lilly and Company, Regeneron Pharmaceuticals Inc., Sun Pharmaceutical Industries Ltd., Beximco Pharmaceuticals Limited, Atea Pharmaceuticals Inc., Enanta Pharmaceuticals Inc., RedHill Biopharma Ltd., Synairgen plc, Dr. Reddy’s Laboratories Ltd., Aurobindo Pharma Ltd., Lupin Limited, Natco Pharma Ltd., Zydus Lifesciences Ltd., Viatris Inc., Teva Pharmaceutical Industries Ltd., Hikma Pharmaceuticals PLC, Alkem Laboratories Ltd., Torrent Pharmaceuticals Ltd., Apotex Inc., Mylan N.V.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/specific-antiviral-drugs-for-covid-19-global-market-report

Which Regions Are Projected To Dominate The Specific Antiviral Drugs For COVID 19 Market In The Coming Years?

North America was the largest region in the specific antiviral drugs for COVID 19 market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the specific antiviral drugs for covid 19 market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Specific Antiviral Drugs For COVID 19 Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=24713&type=smp

Browse Through More Reports Similar to the Global Specific Antiviral Drugs For COVID 19 Market 2026, By The Business Research Company

Antivirals Market Report 2026

https://www.thebusinessresearchcompany.com/report/antivirals-global-market-report

The Antiviral And Antimicrobial Coatings Market Report 2026

https://www.thebusinessresearchcompany.com/report/the-antiviral-and-antimicrobial-coatings-global-market-report

Antiviral Combination Therapy Market Report 2026

https://www.thebusinessresearchcompany.com/report/antiviral-combination-therapy-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

#What Are The Current (2025) And Forecast (2029) Sizes Of The Specific Antiviral Drugs For COVID 19 Market?

The market size for specific antiviral drugs targeting Covid-19 has experienced rapid expansion in recent years. It is projected to expand from $13 billion in 2024 to reach $15.23 billion in 2025, driven by a compound annual growth rate (CAGR) of 17.1%. Historically, this growth has been attributed to factors such as rising hospitalization due to severe cases, increasing government funding for antiviral research, a growing preference for targeted therapeutics over generic treatments, rising awareness regarding early antiviral intervention, and increasing collaborations among pharmaceutical companies.

The specific antiviral drugs for covid 19 market size is anticipated to experience substantial growth over the next few years, projected to reach $28.43 billion by 2029 with a compound annual growth rate (CAGR) of 16.9%. This expansion during the forecast period can be attributed to a heightened focus on pandemic preparedness, an increasing number of clinical trials, a growing demand for effective COVID-19 treatment options, the rising prevalence of COVID-19 variants, and the expanding acceptance of oral antiviral therapies. Significant trends expected during this period include innovation in broad-spectrum antiviral formulations, the integration of artificial intelligence into drug discovery, advancements in personalized antiviral therapies, novel approaches in combination therapy, and the incorporation of genomic data to target viral mutations.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24713&type=smp

What Are The Key Drivers Of Growth In The Specific Antiviral Drugs For COVID 19 Market?

An increase in COVID-19 cases is anticipated to drive future expansion within the specific antiviral drugs for the COVID-19 market. COVID-19 cases are defined as individuals confirmed to be infected with the SARS-CoV-2 virus, the causative agent of COVID-19. This surge in COVID-19 cases stems from the appearance of novel variants capable of more facile transmission and partial evasion of immunity acquired from vaccinations or previous infections. These specialized antiviral medications for COVID-19 play a role in lessening the illness’s intensity and length, thereby enhancing patient recovery and decreasing the total impact of COVID-19 cases. To illustrate, data from May 2023, provided by the US government’s Centers for Disease Control and Prevention, showed that COVID-19 fatalities with co-existing causes averaged 4.5 contributing conditions in 2022, an increase from 4.2 in 2021. Consequently, the expanding volume of COVID-19 infections fuels the development of the specific antiviral drugs for the COVID-19 market.

What Are The Key Segments In The Specific Antiviral Drugs For COVID 19 Market?

The specific antiviral drugs for covid 19 market covered in this report is segmented –

1) By Type: Tablet, Injection

2) By Indication: Hospitalized Patients, Non-Hospitalized Patients, Preventive Treatment

3) By Drug Class: Nucleoside Analogues, Protease Inhibitors, Ribonucleic Acid Polymerase Inhibitors, Entry Inhibitors, Monoclonal Antibodies

4) By Route Of Administration: Oral, Intravenous, Subcutaneous, Inhalation

5) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Other Distribution Channels

Subsegments

1) By Tablet: Oral Antiviral Tablets, Combination Antiviral Tablets, Extended-Release Tablets

2) By Injection: Intravenous (IV) Antiviral Injections, Intramuscular (IM) Antiviral Injections, Subcutaneous Antiviral Injections

What Are The Latest Industry Trends Transforming The Specific Antiviral Drugs For COVID 19 Market?

Leading companies operating within the specific antiviral drugs for the COVID-19 market are concentrating on developing novel treatments, particularly oral antiviral therapies, to enhance both the availability and efficacy of care. Oral antiviral therapies are medications consumed by mouth designed to halt the replication of viruses such as COVID-19, presenting a practical and potent treatment solution. As an illustration, in January 2022, Lupin Limited, an India-based pharmaceutical company, launched the antiviral medication Molnupiravir under the brand name Molnulup, aimed at treating high-risk adult patients afflicted with COVID-19. This oral drug is intended for adults experiencing mild to moderate COVID-19 who are prone to developing severe illness. Molnupiravir functions by preventing the SARS-CoV-2 virus from replicating, thereby contributing to a reduction in viral load and disease severity. Its maximum effectiveness is observed when administered within five days of symptom appearance, proving especially beneficial for individuals with co-existing conditions like obesity, advanced age, diabetes, or cardiovascular disease.

Which Industry Leaders Are Driving Innovation Across The Specific Antiviral Drugs For COVID 19 Market?

Major companies operating in the specific antiviral drugs for covid 19 market are Pfizer Inc., Johnson and Johnson, Roche Holding AG, Merck And Co. Inc., Novartis AG, GSK plc, Eli Lilly and Company, Gilead Sciences Inc., Regeneron Pharmaceuticals Inc, Hetero Drugs Limited, Sun Pharmaceutical Industries Limited, Shionogi and Co. Ltd., Cipla Limited, Beximco Pharmaceuticals Limited, BioCryst Pharmaceuticals Inc., Atea Pharmaceuticals Inc., Enanta Pharmaceuticals Inc., RedHill Biopharma Ltd., Aligos Therapeutics Inc., Synairgen plc

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/specific-antiviral-drugs-for-covid-19-global-market-report

Which Region Currently Holds The Largest Share Of The Specific Antiviral Drugs For COVID 19 Market?

North America was the largest region in the specific antiviral drugs for COVID 19 market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the specific antiviral drugs for covid 19 market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Specific Antiviral Drugs For COVID 19 Market Report:

https://www.thebusinessresearchcompany.com/customise?id=24713&type=smp

Browse Through More Reports Similar to the Global Specific Antiviral Drugs For COVID 19 Market 2025, By The Business Research Company

Antivirals Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/antivirals-global-market-report

The Antiviral And Antimicrobial Coatings Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/the-antiviral-and-antimicrobial-coatings-global-market-report

Antiviral Combination Therapy Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/antiviral-combination-therapy-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Large Is the Specific Antiviral Drugs For COVID 19 Market Expected to Be in 2029?

The market size for specific antiviral drugs for covid 19 has witnessed rapid expansion in the recent past. Forecasted to increase from $13 billion in 2024, it is expected to reach $15.23 billion by 2025, with a compound annual growth rate (CAGR) of 17.1%. The historical period growth has been influenced by factors such as the increasing hospital admissions due to severe cases, increment of government grants for antiviral research, a growing preference for targeted therapeutics over generic treatments, heightened awareness about the need for early antiviral intervention, and escalating cooperative efforts between pharmaceutical companies.

The market size for specific antiviral drugs for covid 19 is anticipated to experience swift expansion in the coming years, ballooning to $28.43 billion in 2029 with a compound annual growth rate (CAGR) of 16.9%. The predicted growth during this period is linked to the heightened emphasis on pandemic readiness, increased instances of clinical trials, escalating demand for efficient COVID-19 treatment methods, rising occurrences of COVID-19 variations, and increased adoption of oral antiviral treatments. Expectations during the forecast period point towards innovations in broad-spectrum antiviral formulations, usage of artificial intelligence in drug discovery, advancements in personalized antiviral therapies, novel approaches in combination therapy, and the application of genomic data in addressing viral mutations.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24713&type=smp

What Are The Contributors To Demand In The Specific Antiviral Drugs For COVID 19 Market?

The escalation in COVID-19 instances is projected to fuel the expansion of the specific antiviral drugs market for COVID-19 going forward. When referring to COVID-19 cases, it denotes individuals who have been diagnosed positive for the SARS-CoV-2 virus that causes COVID-19. The surge in COVID-19 cases is attributable to the surfacing of new variants that transmit more readily and can partially dodge immunity from vaccinations or prior infections. The use of specific antiviral drugs for treating COVID-19 can help mitigate the severity and length of the ailment, thereby improving patient recovery rates and lessening the overall impact of COVID-19 instances. For example, as per data from the US-based government body, the Centers for Disease Control and Prevention, in May 2023, the average number of contributing conditions listed in COVID-19 death cases where additional causes of death were included, rose from 4.2 in 2021 to 4.5 in 2022. Consequently, the rapid surge in COVID-19 cases propels the expansion of the specific antiviral drugs market for COVID-19.

What Segmentation Categories Are Included In The Specific Antiviral Drugs For COVID 19 Market Analysis?

The specific antiviral drugs for covid 19 market covered in this report is segmented –

1) By Type: Tablet, Injection

2) By Indication: Hospitalized Patients, Non-Hospitalized Patients, Preventive Treatment

3) By Drug Class: Nucleoside Analogues, Protease Inhibitors, Ribonucleic Acid Polymerase Inhibitors, Entry Inhibitors, Monoclonal Antibodies

4) By Route Of Administration: Oral, Intravenous, Subcutaneous, Inhalation

5) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Other Distribution Channels

Subsegments

1) By Tablet: Oral Antiviral Tablets, Combination Antiviral Tablets, Extended-Release Tablets

2) By Injection: Intravenous (IV) Antiviral Injections, Intramuscular (IM) Antiviral Injections, Subcutaneous Antiviral Injections

What Upcoming Trends Are Expected To Impact The Specific Antiviral Drugs For COVID 19 Market Globally?

Leading corporations serving the COVID-19 specific antiviral drug market are striving to devise innovative therapeutic solutions, including oral antiviral treatments, to boost the efficacy and attainability of treatment. Oral antiviral treatments are drugs consumed orally designed to suppress the multiplication of viruses like COVID-19, thus presenting an efficient and user-friendly treatment alternative. For example, Lupin Limited, a pharmaceutical organization based in India, unveiled its antiviral medication, Molnupiravir, under the brand Molnulup in January 2022, aimed at treating adults with COVID-19 at high risk. This orally administered drug is designed for adults exhibiting mild to moderate COVID-19 symptoms, who are susceptible to progression to severe disease. Molnupiravir functions by curbing the replication of the SARS-CoV-2 virus, assisting in reducing viral burden and disease severity. It demonstrates maximum effectiveness when initiated within five days from the commencement of symptoms and is particularly advantageous for individuals having comorbid conditions like obesity, old age, diabetes, or heart disease.

Who Are The Top-Ranked Companies In The Specific Antiviral Drugs For COVID 19 Market Today?

Major companies operating in the specific antiviral drugs for covid 19 market are Pfizer Inc., Johnson and Johnson, Roche Holding AG, Merck And Co. Inc., Novartis AG, GSK plc, Eli Lilly and Company, Gilead Sciences Inc., Regeneron Pharmaceuticals Inc, Hetero Drugs Limited, Sun Pharmaceutical Industries Limited, Shionogi and Co. Ltd., Cipla Limited, Beximco Pharmaceuticals Limited, BioCryst Pharmaceuticals Inc., Atea Pharmaceuticals Inc., Enanta Pharmaceuticals Inc., RedHill Biopharma Ltd., Aligos Therapeutics Inc., Synairgen plc

Get The Full Report Here:

https://www.thebusinessresearchcompany.com/report/specific-antiviral-drugs-for-covid-19-global-market-report

How Is Specific Antiviral Drugs For COVID 19 Market Adoption Varying Across Different Regions And Sectors?

North America was the largest region in the specific antiviral drugs for COVID 19 market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the specific antiviral drugs for covid 19 market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=24713&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Large Is the Specific Antiviral Drugs For COVID 19 Market Expected to Be in 2029?

The market size for specific antiviral drugs for covid 19 has witnessed rapid expansion in the recent past. Forecasted to increase from $13 billion in 2024, it is expected to reach $15.23 billion by 2025, with a compound annual growth rate (CAGR) of 17.1%. The historical period growth has been influenced by factors such as the increasing hospital admissions due to severe cases, increment of government grants for antiviral research, a growing preference for targeted therapeutics over generic treatments, heightened awareness about the need for early antiviral intervention, and escalating cooperative efforts between pharmaceutical companies.

The market size for specific antiviral drugs for covid 19 is anticipated to experience swift expansion in the coming years, ballooning to $28.43 billion in 2029 with a compound annual growth rate (CAGR) of 16.9%. The predicted growth during this period is linked to the heightened emphasis on pandemic readiness, increased instances of clinical trials, escalating demand for efficient COVID-19 treatment methods, rising occurrences of COVID-19 variations, and increased adoption of oral antiviral treatments. Expectations during the forecast period point towards innovations in broad-spectrum antiviral formulations, usage of artificial intelligence in drug discovery, advancements in personalized antiviral therapies, novel approaches in combination therapy, and the application of genomic data in addressing viral mutations.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24713&type=smp

What Are The Contributors To Demand In The Specific Antiviral Drugs For COVID 19 Market?

The escalation in COVID-19 instances is projected to fuel the expansion of the specific antiviral drugs market for COVID-19 going forward. When referring to COVID-19 cases, it denotes individuals who have been diagnosed positive for the SARS-CoV-2 virus that causes COVID-19. The surge in COVID-19 cases is attributable to the surfacing of new variants that transmit more readily and can partially dodge immunity from vaccinations or prior infections. The use of specific antiviral drugs for treating COVID-19 can help mitigate the severity and length of the ailment, thereby improving patient recovery rates and lessening the overall impact of COVID-19 instances. For example, as per data from the US-based government body, the Centers for Disease Control and Prevention, in May 2023, the average number of contributing conditions listed in COVID-19 death cases where additional causes of death were included, rose from 4.2 in 2021 to 4.5 in 2022. Consequently, the rapid surge in COVID-19 cases propels the expansion of the specific antiviral drugs market for COVID-19.

What Segmentation Categories Are Included In The Specific Antiviral Drugs For COVID 19 Market Analysis?

The specific antiviral drugs for covid 19 market covered in this report is segmented –

1) By Type: Tablet, Injection

2) By Indication: Hospitalized Patients, Non-Hospitalized Patients, Preventive Treatment

3) By Drug Class: Nucleoside Analogues, Protease Inhibitors, Ribonucleic Acid Polymerase Inhibitors, Entry Inhibitors, Monoclonal Antibodies

4) By Route Of Administration: Oral, Intravenous, Subcutaneous, Inhalation

5) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Other Distribution Channels

Subsegments

1) By Tablet: Oral Antiviral Tablets, Combination Antiviral Tablets, Extended-Release Tablets

2) By Injection: Intravenous (IV) Antiviral Injections, Intramuscular (IM) Antiviral Injections, Subcutaneous Antiviral Injections

What Upcoming Trends Are Expected To Impact The Specific Antiviral Drugs For COVID 19 Market Globally?

Leading corporations serving the COVID-19 specific antiviral drug market are striving to devise innovative therapeutic solutions, including oral antiviral treatments, to boost the efficacy and attainability of treatment. Oral antiviral treatments are drugs consumed orally designed to suppress the multiplication of viruses like COVID-19, thus presenting an efficient and user-friendly treatment alternative. For example, Lupin Limited, a pharmaceutical organization based in India, unveiled its antiviral medication, Molnupiravir, under the brand Molnulup in January 2022, aimed at treating adults with COVID-19 at high risk. This orally administered drug is designed for adults exhibiting mild to moderate COVID-19 symptoms, who are susceptible to progression to severe disease. Molnupiravir functions by curbing the replication of the SARS-CoV-2 virus, assisting in reducing viral burden and disease severity. It demonstrates maximum effectiveness when initiated within five days from the commencement of symptoms and is particularly advantageous for individuals having comorbid conditions like obesity, old age, diabetes, or heart disease.

Who Are The Top-Ranked Companies In The Specific Antiviral Drugs For COVID 19 Market Today?

Major companies operating in the specific antiviral drugs for covid 19 market are Pfizer Inc., Johnson and Johnson, Roche Holding AG, Merck And Co. Inc., Novartis AG, GSK plc, Eli Lilly and Company, Gilead Sciences Inc., Regeneron Pharmaceuticals Inc, Hetero Drugs Limited, Sun Pharmaceutical Industries Limited, Shionogi and Co. Ltd., Cipla Limited, Beximco Pharmaceuticals Limited, BioCryst Pharmaceuticals Inc., Atea Pharmaceuticals Inc., Enanta Pharmaceuticals Inc., RedHill Biopharma Ltd., Aligos Therapeutics Inc., Synairgen plc

Get The Full Report Here:

https://www.thebusinessresearchcompany.com/report/specific-antiviral-drugs-for-covid-19-global-market-report

How Is Specific Antiviral Drugs For COVID 19 Market Adoption Varying Across Different Regions And Sectors?

North America was the largest region in the specific antiviral drugs for COVID 19 market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the specific antiviral drugs for covid 19 market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=24713&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Large Is the Specific Antiviral Drugs For COVID 19 Market Expected to Be in 2029?

The market size for specific antiviral drugs for covid 19 has witnessed rapid expansion in the recent past. Forecasted to increase from $13 billion in 2024, it is expected to reach $15.23 billion by 2025, with a compound annual growth rate (CAGR) of 17.1%. The historical period growth has been influenced by factors such as the increasing hospital admissions due to severe cases, increment of government grants for antiviral research, a growing preference for targeted therapeutics over generic treatments, heightened awareness about the need for early antiviral intervention, and escalating cooperative efforts between pharmaceutical companies.

The market size for specific antiviral drugs for covid 19 is anticipated to experience swift expansion in the coming years, ballooning to $28.43 billion in 2029 with a compound annual growth rate (CAGR) of 16.9%. The predicted growth during this period is linked to the heightened emphasis on pandemic readiness, increased instances of clinical trials, escalating demand for efficient COVID-19 treatment methods, rising occurrences of COVID-19 variations, and increased adoption of oral antiviral treatments. Expectations during the forecast period point towards innovations in broad-spectrum antiviral formulations, usage of artificial intelligence in drug discovery, advancements in personalized antiviral therapies, novel approaches in combination therapy, and the application of genomic data in addressing viral mutations.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24713&type=smp

What Are The Contributors To Demand In The Specific Antiviral Drugs For COVID 19 Market?

The escalation in COVID-19 instances is projected to fuel the expansion of the specific antiviral drugs market for COVID-19 going forward. When referring to COVID-19 cases, it denotes individuals who have been diagnosed positive for the SARS-CoV-2 virus that causes COVID-19. The surge in COVID-19 cases is attributable to the surfacing of new variants that transmit more readily and can partially dodge immunity from vaccinations or prior infections. The use of specific antiviral drugs for treating COVID-19 can help mitigate the severity and length of the ailment, thereby improving patient recovery rates and lessening the overall impact of COVID-19 instances. For example, as per data from the US-based government body, the Centers for Disease Control and Prevention, in May 2023, the average number of contributing conditions listed in COVID-19 death cases where additional causes of death were included, rose from 4.2 in 2021 to 4.5 in 2022. Consequently, the rapid surge in COVID-19 cases propels the expansion of the specific antiviral drugs market for COVID-19.

What Segmentation Categories Are Included In The Specific Antiviral Drugs For COVID 19 Market Analysis?

The specific antiviral drugs for covid 19 market covered in this report is segmented –

1) By Type: Tablet, Injection

2) By Indication: Hospitalized Patients, Non-Hospitalized Patients, Preventive Treatment

3) By Drug Class: Nucleoside Analogues, Protease Inhibitors, Ribonucleic Acid Polymerase Inhibitors, Entry Inhibitors, Monoclonal Antibodies

4) By Route Of Administration: Oral, Intravenous, Subcutaneous, Inhalation

5) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Other Distribution Channels

Subsegments

1) By Tablet: Oral Antiviral Tablets, Combination Antiviral Tablets, Extended-Release Tablets

2) By Injection: Intravenous (IV) Antiviral Injections, Intramuscular (IM) Antiviral Injections, Subcutaneous Antiviral Injections

What Upcoming Trends Are Expected To Impact The Specific Antiviral Drugs For COVID 19 Market Globally?

Leading corporations serving the COVID-19 specific antiviral drug market are striving to devise innovative therapeutic solutions, including oral antiviral treatments, to boost the efficacy and attainability of treatment. Oral antiviral treatments are drugs consumed orally designed to suppress the multiplication of viruses like COVID-19, thus presenting an efficient and user-friendly treatment alternative. For example, Lupin Limited, a pharmaceutical organization based in India, unveiled its antiviral medication, Molnupiravir, under the brand Molnulup in January 2022, aimed at treating adults with COVID-19 at high risk. This orally administered drug is designed for adults exhibiting mild to moderate COVID-19 symptoms, who are susceptible to progression to severe disease. Molnupiravir functions by curbing the replication of the SARS-CoV-2 virus, assisting in reducing viral burden and disease severity. It demonstrates maximum effectiveness when initiated within five days from the commencement of symptoms and is particularly advantageous for individuals having comorbid conditions like obesity, old age, diabetes, or heart disease.

Who Are The Top-Ranked Companies In The Specific Antiviral Drugs For COVID 19 Market Today?

Major companies operating in the specific antiviral drugs for covid 19 market are Pfizer Inc., Johnson and Johnson, Roche Holding AG, Merck And Co. Inc., Novartis AG, GSK plc, Eli Lilly and Company, Gilead Sciences Inc., Regeneron Pharmaceuticals Inc, Hetero Drugs Limited, Sun Pharmaceutical Industries Limited, Shionogi and Co. Ltd., Cipla Limited, Beximco Pharmaceuticals Limited, BioCryst Pharmaceuticals Inc., Atea Pharmaceuticals Inc., Enanta Pharmaceuticals Inc., RedHill Biopharma Ltd., Aligos Therapeutics Inc., Synairgen plc

Get The Full Report Here:

https://www.thebusinessresearchcompany.com/report/specific-antiviral-drugs-for-covid-19-global-market-report

How Is Specific Antiviral Drugs For COVID 19 Market Adoption Varying Across Different Regions And Sectors?

North America was the largest region in the specific antiviral drugs for COVID 19 market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the specific antiviral drugs for covid 19 market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=24713&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model